Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by TMAZZ21on Mar 07, 2023 8:41am

268 Views

Post# 35323208

Cost to Roche to buyout Oncolytics Biotech

Let me know if my math is right!

If we were to assume that Roche was to buy us out for $5B, it would cost Roche share price to errode by 0.76cents

Based on Roche current market value of $236B.
So 5B/236B x $36 current share price= 0.76cents for a $5B buyout
or 0.38cents for a 2.5B buyout
Thats barely a drop in the bucket
At some point a Big Pharma will come to realize that the cost is peanuts compared to the odds of anticipated returns!

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1